Centaurus Financial’s Standard BioTools LAB Stock Holding History

Centaurus Financial’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,500	Closed	-$9K	–	1366
2018 Q2	$9K	Buy	+1,500	New	+$8.55K	﹤0.01%	1597

Other funds holding LAB

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Centaurus Financial's LAB Position: Q3 2018 in Review

Centaurus Financial sold out of Standard BioTools (LAB) in Q3 2018, closing a stake of 1,500 shares — an estimated $9K sold.

Centaurus Financial first reported a position in LAB in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 79 funds tracked by Wall St. Rank hold LAB as of Q3 2018.

Centaurus Financial reported no remaining Standard BioTools position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 1,500 Standard BioTools shares in Q3 2018, an estimated $9K.
Centaurus Financial first reported a position in Standard BioTools in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Standard BioTools position peaked at $9K in Q2 2018.
79 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.